2-{4-[2(R)-(2-Carboxyethylaminocarbonyl)pyrrolidine-1-sulfonyl]benzoylamino}-pentane-(S)-dioic acid | 300593-99-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 肽模拟物
• 英文名称: 2-{4-[2(R)-(2-Carboxyethylaminocarbonyl)pyrrolidine-1-sulfonyl]benzoylamino}-pentane-(S)-dioic acid
• 英文别名: n-[4-[[Glutamic acid]-carbonyl]-benzene-sulfonyl-d-prolinyl]-3-amino-propanoic acid；(2S)-2-[[4-[(2R)-2-(2-carboxyethylcarbamoyl)pyrrolidin-1-yl]sulfonylbenzoyl]amino]pentanedioic acid
• CAS: 300593-99-1
• 化学式: C₂₀H₂₅N₃O₁₀S
• 分子量: 499.499
• InChiKey: SRAHBOKVSSZEHQ-LSDHHAIUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  34
• 可旋转键数：
  12
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  216
• 氢给体数：
  5
• 氢受体数：
  11

文献信息

• TOSYLPROLINE ANALOGS AS THYMIDYLATE SYNTHASE INHIBITORS
  申请人：Sunesis Pharmaceuticals, Inc.

  公开号：EP1252141A1

  公开（公告）日：2002-10-30
• US6143776A
  申请人：——

  公开号：US6143776A

  公开（公告）日：2000-11-07
• [EN] TOSYLPROLINE ANALOGS AS THYMIDYLATE SYNTHASE INHIBITORS<br/>[FR] ANALOGUES DE TOSYLPROLINE UTILISES COMME INHIBITEURS DE LA THYMIDYLATE SYNTHASE
  申请人：SUNESIS PHARMACEUTICALS INC

  公开号：WO2001056987A1

  公开（公告）日：2001-08-09

  Tosylproline analogs of formula (I), where R1 is -COOH, -CONH¿2?, -SO3H, -SO2NH2, -PO3H2; R?2¿ is C¿1-16? alkyl optionally substituted with -COOH, -CONH2, -CONHR?3¿, -CONHCOR4, -CONHSO¿2?R?4, -SO¿3H, -SO2NH2, -SO2NHR3, -SO2NHCOR4, -SO2NHSO2R4, -PO3H2, -4-(1,2,3-triazolyl), -5-tetrazolyl, -5-(3-oxo-1,2,4-triazolyl), -S(O)m-4-(1,2,3-triazolyl), -S(O)m-5-tetrazolyl, or -S(O)m-5-(3-oxo-1,2,4-triazolyl); R3 is a group such that R3-NH2 is an amino acid; R4 is C¿1-4? alkyl, trifluoromethyl, or phenyl optionally substituted with methyl, trifluoromethyl, or nitro; m is 0, 1, or 2; each X and Y, which may be the same or different, is independently selected from methyl, ethyl, isopropyl, ethenyl, ethynyl, fluoro, chloro, bromo, methylthio, hydroxy, methoxy, carboxy, and methoxycarbonyl; n is 0, 1, 2, or 3; p is 0, 1, or 2; q is 1 or 2; R?5¿ is -COOH, -CONH¿2?, -CONHR?2, -SO¿3H,-SO2NH2, -SO2NHR2, or -PO¿3?H2, as an individual stereoisomer or mixture of stereoisomers, or a pharmaceutically acceptable salt or ester thereof, methods of making them, pharmaceutical compositions containing them, and methods for their use. The compounds are thymidylate synthase inhibitors; and are useful as anti-tumor agents and as anti-parasitics, anti-bacterials, anti-fungals, and anti-virals.